Reversal of lineage plasticity in RB1/TP53-deleted prostate cancer through FGFR and Janus kinase inhibition
W. Karthaus, J. Chan, M. Setty, J. Love, S. Zaidi, Z.-N. Choo, S. Persad, J. LaClair, K. Lawrence, O. Chaudhary, T. Xu, I. Masilionis, L. Mazutis, R. Chaligne, D. Pe'er, C. Sawyers
This study identifies a pharmacological strategy to reverse lineage plasticity in prostate cancer by inhibiting FGFR and Janus kinase pathways.
bioRxiv · Nov 1, 2021 · PreprintCancer Biology